CIK 0001800315 · Non-accelerated filer<br>Smaller reporting company
Damora Therapeutics, Inc.
Sign in to watch- Ticker
- DMRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371957007
- Phone
- (781) 281-9020
- Business address
- 100 FIFTH AVENUE, SUITE 700, WALTHAM, MA, 02451
- Former names
- Galecto, Inc., Galecto Inc.
- 4 Grant or award Chief Operating Officer acquired 190,376 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 8-K Event Regulation FD disclosure
- 4 Grant or award Chief Medical Officer acquired 264,629 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Executive Officer sold 700 shares at $21.38 ($14,966)
- 4 Open-market sale General Counsel sold 255 shares at $21.38 ($5,452)
- 4 Open-market sale Chief Financial Officer sold 135 shares at $21.41 ($2,890)
- 8-K Event Unregistered share sale · Executive or director change
- S-8 Other Securities Offered to Employees in Benefit Plans
- DEF 14A Proxy Proxy Statement
- 424B3 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- PRE 14A Proxy Proxy Statement (Preliminary)
- S-3 Offering Registration Statement
- 8-K/A Event Bylaws or fiscal year change
- SCHEDULE 13G Stake Statement of Beneficial Ownership
Page 4 of 18 · 353 filings